Publications

Clinical Cancer Research

Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors

Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JH

Clinical Cancer Research

Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients

Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R, Aldape K

Neuro-Oncology

The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses

Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger AB

Cancer Research

A novel small molecule inhibitor of STAT3 reverses immune tolerance in malignant glioma patients

Hussain SF, Kong L-Y, Jordan J, Conrad C, Madden T, Fokt I, Priebe W, Heimberger AB

Clinical Cancer Research

A novel inhibitor of STAT3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells

Kong L-Y, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, Qiao W, Fuller GN, Fokt I, Grimm EA, Schmittling RJ, Archer Jr GE, Sampson JH, Priebe W, Heimberger AB

Clinical Cancer Research

Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas

Heimberger AB, Reina-Ortiz C, Yang DS, Sun W, Abou-Ghazal M, Qiao W, Hiraoka N, Fuller GN

Clinical Cancer Research

The incidence, correlation with tumor infiltrating inflammation, and prognosis of p-STAT3 expression in human gliomas

Abou-Ghazal M, Yang DS, Qiao W, Reina-Ortiz C, Wei J, Kong L-K, Fuller GN, Hiraoka N, Priebe W, Sawaya R, Heimberger AB

Clinical Cancer Research

Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immune therapeutic response

Kong LY, Wu A, Doucette T, Wei J, Priebe W, Fuller G, Qiao W, Sawaya R, Rao G, Heimberger AB

Neuro-Oncology

Glioma cancer stem cells induce immunosuppressive macrophages/microglia

Wu A, Wei J, Kong LY, Wang Y, Priebe W, Sawaya R, Heimberger AB

Journal of Clinical Oncology

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III (EGFRvIII) peptide vaccination in patients with newly-diagnosed glioblastoma (GBM)

Heimberger AB*, Sampson JH*, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE II, McLendon RL, Mitchell DA, Reardon DA, Sawaya R, Schmittling RJ, Shi W, Vredenburgh J, Bigner DD (*Co-lead authors)

Molecular Cancer Therapeutics

Glioblastoma cancer-initiating cells inhibit T cell proliferation and effector responses by the STAT3 pathway

Wei J, Barr J, Kong L-Y, Wang Y, Wu A, Sharma AK, Gumin J, Henry V, Colman H, Priebe W, Sawaya R, Lang FF, Heimberger AB

Neuro-Oncology

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma

Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, Gilbert MR, Herndon II JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling R, Shi W, Vredenburgh J, Bigner DD, Heimberger AB

Oncotarget

Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma

de Groot J, Liang J, Kong LY, Wei J, Piao Y, Fuller G, Qiao W, Heimberger AB

Neuro-Oncology

Signal Transducer and Activator of Transcription 3 Promotes Angiogenesis and Drives Malignant Progression in Glioma

Doucette TA, Kong LY, Yang Y, Ferguson SD, Yang J, Wei J, Qiao W, Fuller GN, Bhat KP, Aldape K, Priebe W, Bogler O, Heimberger AB, Rao G

Cancer Immunology Research

Immune heterogeneity of glioblastoma subtypes: Extrapolation from the cancer genome atlas

Doucette TA, Rao G, Rao A, Shen L, Aldape K, Wei J, Dziurzynski K, Gilbert M, Heimberger AB

Cancer Research

miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma

Wei J, Wang F, Kong LY, Xu S, Doucette T, Ferguson SD, Yang Y, McEnery K, Jethwa K, Gjyshi O, Qiao W, Levine NB, Lang FF, Rao G, Fuller GN, Calin GA, Heimberger AB

Journal of the National Cancer Institute

Effect of miR-142-3p inhibits the M2 macrophage and exerts therapeutic efficacy against murine glioblastoma

Xu S, Wei J, Wang F, Kong LY, Ling XY, Doucette T, Yang Y, Yaghi N, Qiao W, Li XG, Lang FF, Rao G, Fuller GN, Calin GA, Heimberger AB

Cancer Immunology Research

Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy

Schrand B, Berezhnoy A, Brenneman R, Williams A, Levay A, Kong LY, Rao G, Zhou S, Heimberger AB, Gilboa E

Neuro-Oncology

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study

Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD, Mrugala MM, Jensen R, Baehring JM, Sloan A, Archer GE, Bigner DD, Cruickshank S, Green JA, Keler T, Davis TA, Heimberger AB, Sampson JH

Journal of the National Cancer Institute

FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas

Yan J, Kong LY, Hu J, Gabrusiewicz K, Dibra D, Xia X, Heimberger AB, Li S

Neuro-Oncology

PD-L1 expression and prognostic impact in glioblastoma

Nduom EK, Wei J, Yaghi NK, Huang N, Kong LY, Gabrusiewicz K, Ling X, Zhou S, Ivan C, Chen JQ, Burks JK, Fuller GN, Calin GA, Conrad CA, Creasy C, Ritthipichai K, Radvanyi L, Heimberger AB